Follicle-stimulating hormone, or FSH, has become the laboratory shorthand for menopause. The shorthand is useful, but only up to a point. FSH usually rises as ovarian function changes, yet a single number can mislead during perimenopause. For most midlife women, age, symptoms, bleeding pattern, and medical context still carry more weight than one blood result.
Why FSH rises in midlife
FSH is made by the pituitary gland and tells ovarian follicles to mature. As the pool of responsive follicles declines, the brain often sends a louder signal, so FSH tends to rise. That basic physiology is not controversial; the problem is that the menopausal transition is not a clean switch from normal to abnormal. It is a moving endocrine state, with oestradiol, inhibin, ovulation, and bleeding patterns changing unevenly from cycle to cycle.
The current staging language reflects that complexity. STRAW+10, the reproductive-ageing framework used in research and clinical guidance, places most of the weight on menstrual-cycle pattern rather than a single hormone value. The NCBI summary of menopausal staging describes the transition as cycle variability followed by longer gaps between periods, with laboratory findings treated as supportive rather than decisive.
Why one result can mislead
A high FSH result can fit with late perimenopause or menopause. A normal result does not reliably exclude it. The European Society of Endocrinology’s 2025 clinical practice guideline makes this point directly: for women older than 45 with typical symptoms, biochemical testing for diagnosis or management of perimenopause or menopause is not necessary, partly because FSH can fluctuate for years before and around the final menstrual period.
That is the part many home-testing adverts flatten. FSH is not useless; it is noisy. A woman may test on a lower-FSH day, especially earlier in the transition, and still be having night sweats, cycle changes, sleep disruption, or vaginal symptoms driven by the same ovarian transition. Another may have a raised result and assume every symptom must be hormonal, when anaemia, thyroid disease, medication effects, depression, or sleep apnoea may also need attention.
The attraction of a test is understandable. Menopause care has often asked women to tolerate uncertainty for too long, and a number can feel like evidence that the body is not simply being difficult. The trouble is that validation and diagnosis are not the same task. A result can help start a conversation, but it should not end one, especially when the symptoms affect sleep, mood, sex, work, and metabolic health at the same time.
What longitudinal studies add
Repeated measures show why clinicians are cautious. A UK cohort study in Scientific Reports followed 1,608 women with repeat hormone measurements through natural menopause and found that reproductive age and chronological age both shaped hormone trajectories. The cohort analysis reported that FSH and LH rose around menopause and then declined after several postmenopausal years, while body mass index, smoking, and parity were associated with different patterns.
Trajectory work from the Study of Women’s Health Across the Nation also found that oestradiol and FSH do not move through one universal pattern. A PubMed-indexed analysis of hormone trajectories reported substantial variability in oestradiol and FSH patterns across the transition. That does not make FSH meaningless. It means the result is best read as one clue in a clinical story, not the story itself.
When FSH testing is useful
There are situations where FSH earns its place. The European Society of Endocrinology guideline recommends considering premature ovarian insufficiency in women under 40 with menstrual irregularity, subfertility, or vasomotor symptoms, and supports biochemical testing in that setting. It also says testing for perimenopause or menopause can be considered in women aged 40 to 45, where the diagnosis has more consequence and symptoms may overlap with other conditions.
Testing can also help when the menstrual pattern is hard to interpret, such as after hysterectomy when the ovaries remain, or when hormonal contraception masks natural bleeding. Even then, the result has to be interpreted around medication use, timing, age, symptoms, and the reason for testing. FSH can answer a narrower question than many people want it to answer.
What FSH cannot decide
FSH does not tell a woman whether she should start menopausal hormone therapy. Treatment decisions are usually based on symptoms, risk profile, preferences, contraindications, and the balance of likely benefit and harm. The same European guideline recommends a holistic approach, not a sole focus on hormone therapy, and advises that women who are candidates for therapy should be counselled on benefits, risks, and options before shared decision-making.
FSH also does not measure how well the brain is coping with the transition. Oestrogen receptors are present in brain regions involved in thermoregulation, sleep, and cognition, which is one reason menopause can feel neurological rather than purely reproductive. But translating that biology into an individual treatment plan is still a clinical judgement. A lab number cannot say whether poor sleep is from night sweats, anxiety, alcohol, thyroid disease, caring responsibilities, or all of them at once.
How to read a result in context
The first question is age. A 38-year-old with skipped periods and hot flushes is not the same clinical problem as a 52-year-old with the same symptoms. The second is menstrual pattern: cycle variability and skipped periods carry staging information that a single FSH value cannot replace. The third is medication: combined hormonal contraception, progestogen-only methods, fertility treatment, and some endocrine drugs can all complicate interpretation.
The fourth is the symptom pattern. Vasomotor symptoms, sleep disruption, vaginal and urinary symptoms, mood change, migraine shifts, and musculoskeletal aches can cluster around perimenopause, but none is specific enough to diagnose it alone. A careful clinician is not being dismissive by asking about bleeding, sleep, medications, thyroid symptoms, iron status, and cardiometabolic risk. That is the work of separating a hormone transition from its imitators.
What this means in practice
- If you are over 45 with typical menopause symptoms and changing periods, do not assume you need FSH testing to validate the experience.
- If you are under 45, especially under 40, ask for a proper medical assessment rather than relying on a home test.
- Bring a symptom and cycle record to the appointment; dates often say more than a standalone hormone number.
- Ask what decision the test would change before paying for private panels.
- If a result seems inconsistent with your symptoms, discuss repeat testing or alternative explanations rather than treating the number as final.
What we don’t know
We still do not have a simple blood-test threshold that maps neatly onto every woman’s menopause stage, symptoms, future risk, or best treatment. Women’s hormonal health has also been under-studied compared with many other areas of midlife medicine, and much of the public conversation still jumps faster than the evidence. Better assays and longer longitudinal studies may sharpen risk prediction, but they are unlikely to replace clinical context.
FSH is a useful signal when the question is specific and the context is right. It is not a verdict on menopause, brain health, or whether treatment is needed. The most honest reading of the evidence is quieter than the testing market suggests: the number can help, but it should not be asked to do the whole diagnostic job.
Photo: Tima Miroshnichenko on Pexels.